PMID- 38024827
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20231216
IS  - 1844-3117 (Electronic)
IS  - 1844-122X (Print)
IS  - 1844-122X (Linking)
VI  - 16
IP  - 8
DP  - 2023 Aug
TI  - Coq10 for preventing cardiotoxicity in breast cancer patients treated with 
      trastuzumab.
PG  - 1188-1193
LID - 10.25122/jml-2023-0098 [doi]
AB  - Trastuzumab is a successful treatment option for HER2-positive breast cancer, but 
      a decline in left ventricular ejection fraction (LVEF) and an increase in 
      inflammatory and cardiac enzyme biomarkers can lead to cessation and termination 
      of therapy. This study aimed to investigate the ability of Coenzyme Q10 (Coq10) 
      to avoid these adverse effects. The study included 100 female patients with HER2+ 
      (HER2+3 or amplified gene) breast cancer. All patients underwent standard 
      adjuvant chemotherapy regimens, which involved a four-cycle treatment of 
      Adriamycin, Cyclophosphamide, Docetaxel, and an initial 8 mg/kg loading dose of 
      trastuzumab, followed by a year of 6 mg/kg maintenance doses every three weeks. 
      One group of 50 patients received trastuzumab and a placebo, while the other 50 
      were given trastuzumab and CoQ10 for a full year. The CoQ10-treated group 
      exhibited a statistically significant decrease in levels of monocyte 
      chemoattractant protein-1 (MCP-1), interleukin-6 (IL6), soluble toll-like 
      receptor 4 (sTLR4), and cardiac troponin I (cTnI) compared to the control group 
      (p<0.05). However, there was no significant difference in the mean F2-isoprostane 
      levels between the treated and the control groups at any data collection point. 
      Furthermore, the CoQ10-treated group experienced a significant reduction in the 
      decline of EF levels compared to the control group at all stages except for 
      baseline. According to our findings, Coenzyme Q10 protected patients with HER2+3 
      breast cancer from the cardiotoxicity of trastuzumab by increasing ejection 
      fraction and decreasing inflammatory biomarkers and cardiac enzyme levels.
CI  - (c)2023 JOURNAL of MEDICINE and LIFE.
FAU - Al-Hammadi, Nawal
AU  - Al-Hammadi N
AD  - Kufa Technical Institute, Al-Furat Al-Awsat Technical University, Najaf, Iraq.
FAU - AlSabri, Emad
AU  - AlSabri E
AD  - Middle Euphrates Cancer Therapy Center, Najaf, Iraq.
FAU - Kudhair, Ahmed Hassan
AU  - Kudhair AH
AD  - Department of Biochemistry, Faculty of Medicine, Jabir Ibn Hayyan Medical 
      University, Najaf, Iraq.
FAU - Qassam, Heider
AU  - Qassam H
AD  - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of 
      Kufa, Iraq.
FAU - Hadi, Najah Rayish
AU  - Hadi NR
AD  - Department of Pharmacology and Therapeutics, Faculty of Medicine, University of 
      Kufa, Iraq.
LA  - eng
PT  - Journal Article
PL  - Romania
TA  - J Med Life
JT  - Journal of medicine and life
JID - 101477617
RN  - P188ANX8CK (Trastuzumab)
RN  - EJ27X76M46 (coenzyme Q10)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - Female
MH  - Trastuzumab/adverse effects
MH  - *Breast Neoplasms/drug therapy/genetics
MH  - Cardiotoxicity/etiology/prevention & control/drug therapy
MH  - Stroke Volume
MH  - Receptor, ErbB-2
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Ventricular Function, Left
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10652675
OTO - NOTNLM
OT  - Cyclophosphamide
OT  - Docetaxel
OT  - Trastuzumab
OT  - trastuzumab loading dosage
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/29 18:41
MHDA- 2023/12/01 06:44
PMCR- 2023/08/01
CRDT- 2023/11/29 16:17
PHST- 2023/04/03 00:00 [received]
PHST- 2023/07/03 00:00 [accepted]
PHST- 2023/12/01 06:44 [medline]
PHST- 2023/11/29 18:41 [pubmed]
PHST- 2023/11/29 16:17 [entrez]
PHST- 2023/08/01 00:00 [pmc-release]
AID - JMedLife-16-1188 [pii]
AID - 10.25122/jml-2023-0098 [doi]
PST - ppublish
SO  - J Med Life. 2023 Aug;16(8):1188-1193. doi: 10.25122/jml-2023-0098.